Advertisement

Pharmacy World and Science

, Volume 20, Issue 6, pp 236–237 | Cite as

Informing women about drugs they take during pregnancy: promoting consumers' drug information as integral part of case

  • Maurizio BonatiEmail author
  • Antonio Addis
Article
  • 36 Downloads

Abstract

Although it is recommended that drugs be avoided as much as possible during pregnancy, attitudes towards setting, time and method of the performed studies, and characteristics of the investigated population have been shown to vary. A collaborative and permanent network of different observational points is essential in monitoring and assessing the rational use of drugs, especially during pregnancy. In a context where knowledge is often scant and contradictory, the importance and the need for information on drug use during pregnancy remain unquestioned. If health (drug) information is the interface between those who produce and have knowledge and those who are beneficiaries of such knowledge, information for pregnant women (as well as for all lay people) is mandatory. Initiatives, people and instruments whose job it is to produce and diffuse informations have to be assessed and qualitatively harmonized to adequately answer to questions and needs. Women need information (concerning both pregnancy and drugs) on which to base choices on their own health care (and pregnancy). Clearly, this interaction depends on the kind of information and on the spirit with which it is provided. Thus it is essential that information (especially during pregnancy) be based on transparency and accountability, and it be directed by the principles of equity, effectiveness and affordability.

Pregnancy Drug utilization Drug Information Centres Women 

References

  1. 1.
    Domenighetti G, Grilli R, Liberati A. Promoting consumers' demand for evidence-based medicine. Intl J of Technology Assessment in Health Care 1998;14:97–105.Google Scholar
  2. 2.
    Koren G, Pastuszak A, Ito S. Drugs in pregnancy. N Engl J Med 1998;338:1128–37.Google Scholar
  3. 3.
    Meredith B. Informing patients about the drugs they take. BMJ 1996;313:5.Google Scholar
  4. 4.
    Bonati M, Tognoni G. Health Information Centers in Europe. What is their status? How should they develop? Milano 'Mario Negri' Institute for Pharmacological Research, 1995:112.Google Scholar
  5. 5.
    Hyde CJ. Using the evidence. A need for quantity, not quality? Intl J of Tecnology Assessment in Health Care 1996;12:280–7.Google Scholar
  6. 6.
    CollaborativeGroup on Drug Use in Pregnancy (CGDUP). Medication During Pregnancy: an Intercontinental Cooperative Study. Int I Gynaecol Ostet 1992;39:185–96.Google Scholar
  7. 7.
    Oakley GP, Erickson JD. Vitamin A and Birth Defects. The N Engl J Med 1995;333:1414–5.Google Scholar
  8. 8.
    Medawar C. Potential Benefits of Teaching Children to be Rational Medicine Consumers. In: USP. Children and medicines: Information Isn't Just for Grownups. Proc. Symp., Sept. 29-Oct. 1,1996. Rockville (MD), The United States Pharmacopeia 1997.Google Scholar
  9. 9.
    Hemminki E, Herxheimer A. Should drug information be an integral part of health care? J Roy Coll Phys Lond 1996;30:104–6.Google Scholar
  10. 10.
    Elliott BJ, Polkinhorn JS. Provision of Consumer Health Information in general practice. BMJ 1994;308:509–10.Google Scholar
  11. 11.
    Kroll L, Barnes J, Jones AL, Stein A. Cancer in Parents: Telling Children. BMJ 1998;316:880.Google Scholar

Copyright information

© Kluwer Academic Publishers 1998

Authors and Affiliations

  1. 1.Laboratory for Mother and Child HealthIstituto di Ricerche Farmacologiche 'Mario Negri'MilanoItaly
  2. 2.Regional Drug Information CenterIstituto di Ricerche Farmacologiche 'Mario Negri', PharmD, ScientistItaly

Personalised recommendations